Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiraj Sen

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Current Problems in Cancer|October 17, 2021
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implicationsRoberto Carmagnani Pestana, Jason Roszik, Roman Groisberg, et al.
Cancers|September 13, 2025
Diagnosis, Treatment, and Unmet Needs of Dedifferentiated Liposarcoma in the United States: A Multidisciplinary Delphi StudyDavid Campbell, Scott Ramsey, David Veenstra, et al.
Cancers|September 5, 2019
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy TargetsJason Roszik, Abir Khan, Anthony P Conley, et al.
Cold Spring Harbor Molecular Case Studies|August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumorsShiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
JCO Clinical Cancer Informatics|March 17, 2022
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical PracticeCarsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, et al.
Molecular and Cellular Biology|January 20, 2011
Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophyJessica M Ellis, Shannon M Mentock, Michael A Depetrillo, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Cancer|February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trialsShiraj Sen, Kenneth Hess, David S Hong, et al.
Cancer|March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumorsFilip Janku, Milind M Javle, Shiraj Sen, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Current Problems in Cancer|October 17, 2021
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implicationsRoberto Carmagnani Pestana, Jason Roszik, Roman Groisberg, et al.
Cancers|September 13, 2025
Diagnosis, Treatment, and Unmet Needs of Dedifferentiated Liposarcoma in the United States: A Multidisciplinary Delphi StudyDavid Campbell, Scott Ramsey, David Veenstra, et al.
Cancers|September 5, 2019
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy TargetsJason Roszik, Abir Khan, Anthony P Conley, et al.
Cold Spring Harbor Molecular Case Studies|August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumorsShiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
JCO Clinical Cancer Informatics|March 17, 2022
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical PracticeCarsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, et al.
Molecular and Cellular Biology|January 20, 2011
Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophyJessica M Ellis, Shannon M Mentock, Michael A Depetrillo, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Cancer|February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trialsShiraj Sen, Kenneth Hess, David S Hong, et al.
Cancer|March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumorsFilip Janku, Milind M Javle, Shiraj Sen, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
Pageof 4